Related Experiment Video
Updated: Oct 28, 2025
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Cardiorenal syndrome: classification, pathophysiology, diagnosis and management. Literature review
Jonathan S Chávez-Iñiguez1, Sergio J Sánchez-Villaseca1, Luz A García-Macías2
1Servicio de Nefrología, Hospital Civil Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Insights
Cardiorenal syndrome involves heart and kidney dysfunction, affecting nearly half of heart failure patients. Management focuses on fluid overload using diuretics and monitoring with biomarkers and imaging, aiming to improve outcomes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiorenal syndrome (CRS) is a complex interplay between heart and kidney dysfunction.
- Nearly 49% of heart failure patients experience kidney dysfunction, increasing morbidity and mortality.
- Pathogenesis involves hemodynamic, hormonal, and immunological factors, often leading to fluid overload.
Purpose of the Study:
- To outline the diagnosis and management of cardiorenal syndrome.
- To highlight the importance of integrated organ assessment in CRS.
- To review current therapeutic strategies for fluid management in CRS.
Main Methods:
- Clinical diagnosis supplemented by biochemical markers (e.g., natriuretic peptides).
- Utilizing lung and heart ultrasound for comprehensive assessment.
- Monitoring urinary sodium levels to guide therapy effectiveness.
Main Results:
- Fluid overload is a key feature requiring effective decongestion.
- A continuous infusion of loop diuretics is the preferred initial strategy.
- Sequential addition of other diuretics and ultrafiltration as a last resort are discussed.
Conclusions:
- Integrated diagnosis using clinical, biochemical, and imaging tools is crucial for CRS.
- Aggressive decongestion strategies are vital for managing fluid overload.
- Long-term, evidence-based therapy is essential to improve quality of life and delay organ function deterioration.
Abstract:
The cardiorenal syndrome is a complex entity in which a primary heart dysfunction causes kidney injury (Types 1 and 2) and vice versa (Types 3 and 4), being either acute or chronic events, or maybe the result of a systemic disease that involves both organs (Type 5). Approximately 49% of heart failure cases present some grade of kidney dysfunction, significantly increasing morbidity and mortality rates. Its pathogenesis involves a variety of hemodynamic, hormonal and immunological factors that in the majority of cases produce fluid overload; the diagnosis and treatment of such constitutes the disease’s management basis. Currently, a clinical based diagnosis is insufficient and the use of biochemical markers, such as natriuretic peptides, or lung and heart ultrasound is required. These tools, along with urinary sodium levels, allow the evaluation of therapy effectiveness. The preferred initial decongestive strategy is based on a continuous infusion of a loop diuretic with a step-up dosing regimen, aiming for a minimal daily urine volume of 3 liters, with the possibility to sequentially add potassium sparing diuretics, thiazide diuretics and carbonic anhydrase inhibitors to reach the diuresis goal, leaving ultrafiltration as a last resource due to its higher rate of complications. Finally, evidence-based therapy should be given to improve quality of life, decrease mortality, and delay the deterioration of kidney and heart function over the long term.
